Evidence map›Paper›PMID 38309043›Full record

ArticleJournal of chromatography. B, Analytical technologies in the biomedical and life sciences2024

Determination of sulfadoxine and pyrimethamine in microvolume human plasma using ultra high performance liquid chromatography-tandam mass spectrometry.

Vong Sok, Florence Marzan, Michelle Roh, Kevin Guo, Jenny Legac, Norah Mwebaza, Grant Dorsey, Philip J Rosenthal, Francesca T Aweeka, Liusheng Huang

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.1field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Trial
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 2 countries.

Vong SokUniversity of California, Department of Clinical Pharmacy, San Francisco, CA 94110, USA.
Florence MarzanUniversity of California, Department of Clinical Pharmacy, San Francisco, CA 94110, USA.
Michelle RohUniversity of California, Institute for Global Health Sciences, San Francisco, CA 94110, USA.
Kevin GuoUniversity of California, Department of Clinical Pharmacy, San Francisco, CA 94110, USA.
Jenny LegacDepartment of Medicine, University of California, San Francisco, CA 94110, USA.
Norah MwebazaInfectious Disease Research Collaboration, Kampala, Uganda; Departments of Clinical Pharmacology and Therapeutics, Makerere University, Kampala, Uganda.
Grant DorseyDepartment of Medicine, University of California, San Francisco, CA 94110, USA.
Philip J RosenthalDepartment of Medicine, University of California, San Francisco, CA 94110, USA.
Francesca T AweekaUniversity of California, Department of Clinical Pharmacy, San Francisco, CA 94110, USA.
Liusheng HuangUniversity of California, Department of Clinical Pharmacy, San Francisco, CA 94110, USA. Electronic address: liusheng.huang@ucsf.edu.
University of California, San Francisco · USGlobal Brain Health Institute · USInfectious Diseases Research Collaboration · UG

Funding

Pharmacological insights into antimalarial exposure, clinical outcomes, and drug resistance in AfricaR01AI117001 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI AWEEKA, FRANCESCA T., ROSENTHAL, PHILIP JON · 2015 to 2024
$7.1M
Optimal chemopreventive regimens to prevent malaria and improve birth outcomes in UgandaU01AI141308 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI DORSEY, MATTHEW G, ROSENTHAL, PHILIP JON · 2020 to 2024
$6.0M
Unbound piperaquine pharmacokinetic exposure in Ugandan pregnant women and children receiving malaria chemopreventionR21AI153848 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI HUANG, LIUSHENG · 2021 to 2022
$444k
NIAID NIH HHS R01 AI117001NIAID NIH HHS U01 AI141308
6 · The paper itself

Abstract

To support the pharmacokinetic study of sulfadoxine (SD) and pyrimethamine (PM) in pregnant women and children, sensitive methods with small sample volume are desirable. Here we report a method to determine SD and PM with microvolume plasma samples: 5 µL plasma samples were cleaned up by protein precipitation with acetonitrile. The deuterated analytes were used as the internal standards. The samples after cleanup were injected onto an ACE Excel SuperC

Indexed as

PyrimethamineTandem Mass SpectrometryAcetonitrilesChildChromatography, High Pressure LiquidFemaleHumansPregnancySulfadoxineAcetonitrilesPyrimethamineSulfadoxineMicrovolumePlasmaPyrimethamineSulfadoxineUHPLC-MS/MS

Identifiers

PMID38309043
PMCPMC11820842
OpenAlexW4391177635

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.